Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer-Reference-Cited by-同舟云学术

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer

Published:2019-11 Issue: Volume:464 Page:5-14
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Fournel Ludovic,Wu Zherui,Stadler Nicolas,Damotte Diane,Lococo Filippo,Boulle Geoffroy^ORCID,Ségal-Bendirdjian Evelyne,Bobbio Antonio,Icard Philippe,Trédaniel Jean,Alifano Marco,Forgez Patricia^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. Lung cancer statistics;Torre;Adv. Exp. Med. Biol.,2016

2. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: results from the randomised phase III OAK study;von Pawel;Eur. J. Canc. Oxf. Engl.,1990

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet Lond. Engl.,2016

4. KEYNOTE-024 investigators, pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N. Engl. J. Med.,2016

5. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater;Reck;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2019

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Centipeda minima and 6-O-angeloylplenolin enhance the efficacy of immune checkpoint inhibitors in non-small cell lung cancer;Phytomedicine;2024-09

2. The Association of Transferrin Receptor with Prognosis and Biologic Role in Intrahepatic Cholangiocarcinoma;Annals of Surgical Oncology;2024-08-23

3. Recent progress of ferroptosis in cancers and drug discovery;Asian Journal of Pharmaceutical Sciences;2024-08

4. Nonlinear association between PD-L1 expression levels and the risk of postoperative recurrence in non-small cell lung cancer;Scientific Reports;2024-07-04

5. The significance of inflammatory markers in prognosticating the effectiveness and safety of immunotherapy in conjunction with chemotherapy during the primary intervention of advanced non-small cell lung carcinoma;Lung Cancer;2024-06